1570-05-4

Basic information

• Product Name: 3,4-BIS(BENZYLOXY)BENZOIC ACID
• Synonyms: 3,4-BIS(BENZYLOXY)BENZOIC ACID;RARECHEM AL BE 0665;3,4-Bis(phenylMethoxy)-benzoic Acid;Benzoic acid,3,4-bis(phenylmethoxy)-
• CAS NO: 1570-05-4
• Molecular Formula: C₂₁H₁₈O₄
• Molecular Weight: 334.37
• Mol File: 1570-05-4.mol
• Article Data: 31

Chemical Properties

• Melting Point: 182 °C
• Boiling Point: 512.7°Cat760mmHg
• Flash Point: 182.2°C
• Appearance: /
• Density: 1.232g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly, Heated), DMSO (Slightly)
• PKA: 4.31±0.10(Predicted)
• CAS DataBase Reference: 3,4-BIS(BENZYLOXY)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-BIS(BENZYLOXY)BENZOIC ACID(1570-05-4)
• EPA Substance Registry System: 3,4-BIS(BENZYLOXY)BENZOIC ACID(1570-05-4)

Safety Data

• Hazardous Substances Data: 1570-05-4(Hazardous Substances Data)

Usage

Uses

3,4-Bis(phenylmethoxy)-benzoic Acid is a useful synthetic intermediate. It is an intermediate used to synthesize Jaboticabin (J210370) which is minor bioactive depside potent to treat chronic obstructive pulmonary disease.

InChI:InChI=1/C21H18O4/c22-21(23)18-11-12-19(24-14-16-7-3-1-4-8-16)20(13-18)25-15-17-9-5-2-6-10-17/h1-13H,14-15H2,(H,22,23)

Upstream product

• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 58605-10-0 methyl 3,5-bis(benzyloxy)benzoate 
• 544-16-1 n-Butyl nitrite 
• 17269-65-7 1-(3,4-bis(benzyloxy)phenyl)propan-1-one 
• 141-52-6 sodium ethanolate 
• 71-43-2 benzene 
• 27628-06-4 1-(3,4-bis(benzyloxy)phenyl)ethan-1-one 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 100-39-0 benzyl bromide 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 100-44-7 benzyl chloride 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 3943-89-3 Ethyl protocatechuate 
• 584-08-7 potassium carbonate 

Downstream Products

• 95822-16-5 3,4-Dibenzyloxy-benzoesaeure-diaethylamid 
• 922509-50-0 3,4-bis-benzyloxy-benzoic acid 2,3-dihydroxy-propyl ester 
• 922509-54-4 3,4-bis-benzyloxy-benzoic acid 2,3-bis-hexadecanoyloxy-propyl ester 
• 1486-70-0 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-methoxy-chromen-4-on 
• 1486-61-9 3',4'-bis(benzyloxy)-5,7-dihydroxy-3-methoxyflavone 
• 870090-75-8 3,4-dibenzyloxy-N-(2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)benzamide 
• 79353-93-8 C₂₃H₂₃NO₄ 
• 1331965-87-7 N-(2,3-bis(benzyloxy)phenyl)-6-iodobenzo[d][1,3]dioxole-5-carboxamide 
• 1331965-91-3 C₃₄H₃₆INO₆Si 
• 1331965-95-7 2,3-bis(benzyloxy)-5-((2-(trimethylsilyl)ethoxy)methyl)-[1,3]dioxolo[4,5-j]phenanthridin-6(5H)-one 
• 18002-44-3 3,4-Bis(phenylmethoxy)benzeneamine 
• 765848-22-4 3,4-Bis-benzyloxy-benzoic acid 4-[ethyl-(6-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amino]-butyl ester 

Relevant articles and documents

Discovery and evaluation of the hybrid of bromophenol and saccharide as potent and selective protein tyrosine phosphatase 1B inhibitors

Protein tyrosine phosphatase 1B (PTP1B) is a key negative regulator of insulin signaling pathway. Inhibition of PTP1B is expected to improve insulin action. Appropriate selectivity and permeability are the gold standard for excellent PTP1B inhibitors. In this work, molecular hybridization-based screening identified a selective competitive PTP1B inhibitor. Compound 10a has IC50 values of 199?nM against PTP1B, and shows 32-fold selectivity for PTP1B over the closely related phosphatase TCPTP. Molecule docking and molecular dynamics studies reveal the reason of selectivity for PTP1B over TCPTP. Moreover, the cell permeability and cellular activity of compound 10a are demonstrated respectively.

Cannabidiol derivative, preparation method and application thereof

The invention discloses a cannabidiol derivative, a preparation method and application thereof, and belongs to the technical field of medicinal chemistry, wherein the cannabidiol derivative is obtained by taking cannabidiol as a main body through a synthesis means, and an anti-tumor activity determination result shows that the cannabidiol derivative prepared by the invention has an inhibition effect on lung cancer cell strains, human breast cancer cell strains, nasopharynx cancer and drug-resistant strains thereof.

Synthesis and comparative structure-activity study of carbohydrate-based phenolic compounds as α-glucosidase inhibitors and antioxidants

Twenty-one natural and unnatural phenolic compounds containing a carbohydrate moiety were synthesized and their structure-activity relationship (SAR) was evaluated for α-glucosidase inhibition and antioxidative activity. Varying the position of the galloyl unit on the 1,5-anhydro -D-glucitol (1,5-AG) core resulted in changes in the α-glucosidase inhibitory activity and notably, particularly strong activity was demonstrated when the galloyl unit was present at the C-2 position. Furthermore, increasing the number of the galloyl units significantly affected the α-glucosidase inhibition, and 2,3,4,6-tetra-galloyl-1,5-AG (54) and 2,3,4,6-tetra-galloyl-d-glucopyranose (61) exhibited excellent activities, which were more than 13-fold higher than the α-glucosidase inhibitory activity of acertannin (37). Moreover, a comparative structure-activity study suggested that a hemiacetal hydroxyl functionality in the carbohydrate core and a biaryl bond of the 4,6-O-hexahydroxydiphenoyl (HHDP) group, which are components of ellagitannins including tellimagrandin I, are not necessary for the α-glucosidase inhibitory activity. Lastly, the antioxidant activity increased proportionally with the number of galloyl units.